Does the media prefer GLSI or QURE?

In the previous week, Greenwich LifeSciences had 4 more articles in the media than uniQure. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 2 mentions for uniQure. uniQure's average media sentiment score of 0.99 beat Greenwich LifeSciences' score of -0.07 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenwich LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ATAI or GLSI?

In the previous week, Greenwich LifeSciences had 3 more articles in the media than Atai Beckley. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 3 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.47 beat Greenwich LifeSciences' score of -0.07 indicating that Atai Beckley is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Greenwich LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, GLSI or DMRA?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenwich LifeSciences N/A N/A -$15.79M -$1.46 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A

Is GLSI or DMRA more profitable?

Damora Therapeutics, Inc. Common Stock's return on equity of -428.30% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -1,042.84% -565.43% Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Does the media prefer GLSI or ARDX?

In the previous week, Greenwich LifeSciences had 4 more articles in the media than Ardelyx. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.93 beat Greenwich LifeSciences' score of -0.07 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenwich LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ardelyx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IMTX or GLSI?

In the previous week, Immatics had 1 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 7 mentions for Immatics and 6 mentions for Greenwich LifeSciences. Immatics' average media sentiment score of 0.12 beat Greenwich LifeSciences' score of -0.07 indicating that Immatics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Greenwich LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Greenwich LifeSciences (GLSI) Competitors

$24.29 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$23.92 -0.37 (-1.52%)

As of 07:49 PM Eastern

Compare

GLSI vs. QURE, ATAI, DMRA, ARDX, and IMTX

Should you buy Greenwich LifeSciences stock or one of its competitors? MarketBeat compares Greenwich LifeSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Greenwich LifeSciences include uniQure (QURE), Atai Beckley (ATAI), Damora Therapeutics, Inc. Common Stock (DMRA), Ardelyx (ARDX), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry.

How does Greenwich LifeSciences compare to uniQure?

Greenwich LifeSciences (NASDAQ:GLSI) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

In the previous week, Greenwich LifeSciences had 4 more articles in the media than uniQure. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 2 mentions for uniQure. uniQure's average media sentiment score of 0.99 beat Greenwich LifeSciences' score of -0.07 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Greenwich LifeSciences has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, uniQure has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Greenwich LifeSciences presently has a consensus price target of $47.50, suggesting a potential upside of 95.55%. uniQure has a consensus price target of $42.83, suggesting a potential upside of 43.35%. Given Greenwich LifeSciences' higher probable upside, research analysts plainly believe Greenwich LifeSciences is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

Greenwich LifeSciences has higher earnings, but lower revenue than uniQure. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A
uniQure	$16.10M	117.05	-$198.97M	-$3.48	N/A

Greenwich LifeSciences has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. uniQure's return on equity of -145.81% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%
uniQure	-1,154.42%	-145.81%	-27.15%

Summary

Greenwich LifeSciences and uniQure tied by winning 7 of the 14 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Greenwich LifeSciences has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%

Greenwich LifeSciences has lower revenue, but higher earnings than Atai Beckley. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	407.78	-$660.05M	-$2.23	N/A
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 26.8% of Atai Beckley shares are held by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Greenwich LifeSciences had 3 more articles in the media than Atai Beckley. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 3 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.47 beat Greenwich LifeSciences' score of -0.07 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Greenwich LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Atai Beckley currently has a consensus price target of $16.00, indicating a potential upside of 253.20%. Greenwich LifeSciences has a consensus price target of $47.50, indicating a potential upside of 95.55%. Given Atai Beckley's stronger consensus rating and higher probable upside, equities analysts plainly believe Atai Beckley is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Atai Beckley has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Summary

Atai Beckley beats Greenwich LifeSciences on 10 of the 15 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Damora Therapeutics, Inc. Common Stock?

Greenwich LifeSciences (NASDAQ:GLSI) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

In the previous week, Greenwich LifeSciences had 3 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 3 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.90 beat Greenwich LifeSciences' score of -0.07 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Damora Therapeutics, Inc. Common Stock's return on equity of -428.30% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Greenwich LifeSciences has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

Greenwich LifeSciences presently has a consensus target price of $47.50, suggesting a potential upside of 95.55%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $42.00, suggesting a potential upside of 87.75%. Given Greenwich LifeSciences' higher probable upside, research analysts clearly believe Greenwich LifeSciences is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Damora Therapeutics, Inc. Common Stock beats Greenwich LifeSciences on 8 of the 13 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Ardelyx?

Greenwich LifeSciences (NASDAQ:GLSI) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by insiders. Comparatively, 5.3% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Greenwich LifeSciences had 4 more articles in the media than Ardelyx. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.93 beat Greenwich LifeSciences' score of -0.07 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ardelyx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Greenwich LifeSciences has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A
Ardelyx	$407.32M	3.29	-$61.60M	-$0.23	N/A

Greenwich LifeSciences currently has a consensus price target of $47.50, suggesting a potential upside of 95.55%. Ardelyx has a consensus price target of $15.70, suggesting a potential upside of 189.67%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Greenwich LifeSciences has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%
Ardelyx	-13.58%	-38.11%	-11.85%

Greenwich LifeSciences has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

Summary

Ardelyx beats Greenwich LifeSciences on 10 of the 15 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Immatics?

Immatics (NASDAQ:IMTX) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Greenwich LifeSciences has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%

Immatics has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

In the previous week, Immatics had 1 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 7 mentions for Immatics and 6 mentions for Greenwich LifeSciences. Immatics' average media sentiment score of 0.12 beat Greenwich LifeSciences' score of -0.07 indicating that Immatics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Greenwich LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

64.4% of Immatics shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Greenwich LifeSciences has lower revenue, but higher earnings than Immatics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	25.05	-$222.26M	-$1.99	N/A
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A

Immatics currently has a consensus price target of $20.80, suggesting a potential upside of 103.92%. Greenwich LifeSciences has a consensus price target of $47.50, suggesting a potential upside of 95.55%. Given Immatics' stronger consensus rating and higher possible upside, research analysts plainly believe Immatics is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Immatics beats Greenwich LifeSciences on 9 of the 14 factors compared between the two stocks.

Get Greenwich LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLSI vs. The Competition

Export

Metric	Greenwich LifeSciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$356.53M	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	N/A	17.93	22.30	24.19
Price / Sales	N/A	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	127.84	6.63	9.84	6.72
Net Income	-$15.79M	$24.20M	$3.57B	$337.19M
7 Day Performance	-16.90%	-3.24%	-1.16%	0.48%
1 Month Performance	2.49%	0.53%	3.85%	5.07%
1 Year Performance	154.35%	47.24%	27.40%	34.25%

Greenwich LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLSI Greenwich LifeSciences	1.516 of 5 stars	$24.29 flat	$47.50 +95.6%	+152.0%	$336.42M	N/A	N/A	3	News Coverage
QURE uniQure	3.4049 of 5 stars	$24.91 +3.0%	$42.83 +72.0%	+84.8%	$1.57B	$18.09M	N/A	500
ATAI Atai Beckley	3.0202 of 5 stars	$4.23 -2.1%	$16.00 +278.3%	+93.2%	$1.56B	$4.09M	N/A	80
DMRA Damora Therapeutics, Inc. Common Stock	2.8609 of 5 stars	$25.09 -0.8%	$43.40 +73.0%	+617.2%	$1.54B	N/A	N/A	40
ARDX Ardelyx	2.8968 of 5 stars	$6.23 +2.0%	$15.70 +152.0%	+43.4%	$1.54B	$407.32M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLSI) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Greenwich LifeSciences (GLSI) Competitors

GLSI vs. QURE, ATAI, DMRA, ARDX, and IMTX

How does Greenwich LifeSciences compare to uniQure?

Summary

How does Greenwich LifeSciences compare to Atai Beckley?

Summary

How does Greenwich LifeSciences compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Greenwich LifeSciences compare to Ardelyx?

Summary

How does Greenwich LifeSciences compare to Immatics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI vs. The Competition

Greenwich LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Greenwich LifeSciences (GLSI) Competitors

GLSI vs. QURE, ATAI, DMRA, ARDX, and IMTX

How does Greenwich LifeSciences compare to uniQure?

Does the media prefer GLSI or QURE?

Which has more risk & volatility, GLSI or QURE?

Do institutionals and insiders hold more shares of GLSI or QURE?

Do analysts rate GLSI or QURE?

Which has higher valuation & earnings, GLSI or QURE?

Is GLSI or QURE more profitable?

Summary

How does Greenwich LifeSciences compare to Atai Beckley?

Is ATAI or GLSI more profitable?

Which has better valuation and earnings, ATAI or GLSI?

Do institutionals & insiders have more ownership in ATAI or GLSI?

Does the media favor ATAI or GLSI?

Do analysts prefer ATAI or GLSI?

Which has more risk & volatility, ATAI or GLSI?

Summary

How does Greenwich LifeSciences compare to Damora Therapeutics, Inc. Common Stock?

Does the media refer more to GLSI or DMRA?

Which has preferable earnings and valuation, GLSI or DMRA?

Do institutionals and insiders believe in GLSI or DMRA?

Is GLSI or DMRA more profitable?

Which has more volatility and risk, GLSI or DMRA?

Do analysts rate GLSI or DMRA?

Summary

How does Greenwich LifeSciences compare to Ardelyx?

Do institutionals & insiders believe in GLSI or ARDX?

Does the media prefer GLSI or ARDX?

Which has stronger valuation and earnings, GLSI or ARDX?

Do analysts rate GLSI or ARDX?

Is GLSI or ARDX more profitable?

Which has more volatility & risk, GLSI or ARDX?

Summary

How does Greenwich LifeSciences compare to Immatics?

Is IMTX or GLSI more profitable?

Which has more volatility and risk, IMTX or GLSI?

Does the media favor IMTX or GLSI?

Do institutionals and insiders hold more shares of IMTX or GLSI?

Which has stronger valuation and earnings, IMTX or GLSI?

Do analysts recommend IMTX or GLSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI vs. The Competition

Greenwich LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools